OBJECTIVE: Ventricular septal defects (VSD) account for 20% of congenital heart defects (CHDs) and the pathogenesis and molecular mechanism have not been elucidated. MicroRNAs (miRs) are small single-stranded, non-coding RNA molecules that regulate gene expression at the post-transcriptional level. Recent research demonstrated that miRs help regulate embryonic cardiac development, cardiac mophogenesis, and cardiomyocyte growth and differentiation and are closely related to the occurrence of CHDs. This study aimed to measure differences in miR expression in maternal serum in patients complicated with fetal muscular VSD. STUDY DESIGN: This was a prospective study including fetuses at risk for CHD (pregestational diabetes, anticonvulsant use, or history of cardiac defects) during 2 nd trimester echocardiographic examination. Fetuses without cardiac abnormalities were marked as control. Fetuses with isolated mVSD were marked as abnormal. Maternal venous serum was collected, RNA extracted, and an expression profile of 797 human miRs was measured using NanoString nCounter technology as counts (molecules/100ng RNA). Expression levels of >2fold increase or <50% decrease compared to control were considered up-or downregulated, respectively. Placentalderived miRs within the entire expression profile were also evaluated separately. RESULTS: miRs profiling was obtained in 6 controls and 7 mVSDs cases. Expression levels ranged from 3-198 counts, indicating relatively low expression. The median count did not vary between normal (20.7) and mVSD (21.4). Of the 797, 12 miRs were significantly upregulated (Fig. 1 ) and 36 miRs downregulated (P<0.01 for both). There were no differences in expression among the 114 known placentally-derived miRs between groups. CONCLUSION: This study identifies a select serum miR expression profile in women with mVSD fetuses in the 2 nd trimester that differs from women with normal fetuses. This approach may provide a quantitative screening tool for confirming fetal CHDs diagnosed by echocardiography. This will be valuable as a biomarker approach for early detection of fetal CHDs in the first trimester to aid diagnosis by fetal echocardiography. .
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with maternal serum HDL quartiles (Figure) . This association remained significant after adjustment for maternal weight, height, and pregnancy -associated hypertension. CONCLUSION: Low circulating levels of HDL at 10-14 weeks are associated with a higher risk for SGA. n¼1, 358, 191, 84, 598 HTN, 11, 427 NND) . RESULTS: NND rates were consistently lower for FGR/SGA neonates born to mothers with HTN than for FGR/SGA neonates without HTN [MWH-US Odds Ratio 0.26 (95% C.I. 0.10, 0.68); MWH-BW OR 0.20 (0.10, 0.37); National-BW OR 0.36 (0.33, 0.39)]. Predicted probabilities of NND with and without HTN at specific gestational ages are shown graphically. CONCLUSION: Gestational-age adjusted NND rates were lower for FGR/SGA pregnancies with HTN than for FGR/SGA pregnancies without HTN. This finding may be attributable to the fact that FGR with HTN is more likely to lead to iatrogenic premature delivery without a fetal indication due to concerns for maternal health. OBJECTIVE: Stillbirth remains unexplained in a significant proportion of fetuses, even after a thorough evaluation. Despite the known contribution of infectious etiologies to this devastating pregnancy outcome, the yield such a workup is of unproven benefit. We aimed to assess the utility of diagnostic tests of maternal and fetal infection in the evaluation of stillbirth. STUDY DESIGN: A single center retrospective study from 1/2011-3/2017 of all women presenting to the hospital with intra-uterine fetal death at or after 20 weeks of gestation. Standard evaluation included a maternal interview, review of medical records, clinical and laboratory inflammatory workup, serology testing (for syphilis, Parvovirus B19, Rubella, CMV, Listeria, Toxoplasmosis, Hepatitis B and C) fetal autopsy, placental pathology and fetal and placental cultures. Additional standard stillbirth workup, including Kleinhauer-Betke, blood for group and screen and HbA1C, was obtained. An infectious etiology was considered the underlying cause of stillbirth if it was supported by at least two diagnostic tests (concordant pathogenic maternal and fetal cultures, histological chorioamnionitis, maternal symptoms of infection or positive serologies) and there was no other probable cause. RESULTS: During the 7-year study period, 228 cases of stillbirth occurred. Placental histological findings diagnostic of overt chorioamnionitis were observed in 69 (30.3%) cases. Serologies of acute infection were positive in 11 (4.8%) of the cases. In 39 cases the placental and abortus cultures were positive for the same pathogen. An infectious etiology was the probable cause of stillbirth, supported by at least two diagnostic tests, in 35 cases (15.3%). The mean gestational age of stillbirth caused by an infection was 29 weeks, while for a non-infectious etiology it was 32 weeks (p¼0.005). CONCLUSION: Diagnostic tests of maternal and fetal infection are valuable in the investigation of stillbirth, particularly before 30 weeks of gestation and should be considered a part of standard evaluation.
